Aktuella utlysningar, vecka 19, 2022
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Research funding - Swedish Breast Cancer Association
Support breast cancer research with patient-centred clinical grounding. Projects are supported for up to three years.
Closing date: 3 June 2022
Postdoktoralt stipendium - Hjärnfonden
Hjärnfonden stödjer forskning rörande hjärnans och övriga nervsystemets sjukdomar, skador och funktionsnedsättningar, men även den friska hjärnan med dess normala funktioner och utveckling.
Stipendierna är öppna för sökande med svensk doktorsexamen och ansökes för en period om 24 månader på heltid (alternativt utnyttjas minst på halvtid varvid stipendietiden förlängs).
Closing date: 7 June 2022
Forskningsmedel - Strålsäkerhetsmyndigheten
Strålsäkerhetsmyndigheten utlyser härmed forskningsmedel för kompetensstöd till en forskargrupp inom området strålningsbiologi. Medel uppgår till maximalt SEK 3 miljoner, inklusive indirekta kostnader, över tre år.
Closing date: 30 July 2022
International network grants for the sustainable development goals - Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)
Support joint projects with one or more global partners outside Europe related to achieving the sustainable development goals. Grants are worth up to SEK 200,000 for up to one year.
Closing date: 25 August 2022
Apply to this year's Science & SciLifeLab Prize for Young Scientists!
Apply now for the Science & SciLifeLab Prize for Young Scientists, an annual prize awarded to early-career scientists.
If selected as a winner, you will have your essay published by Science, win up to USD 30,000 and be invited to Sweden to receive your award, present your research and meet with leading scientists in your field.
Get ready for a life-changing moment in your scientific career!
Closing date: 15 July 2022
KI Lifestyle4Health: Best paper award for junior researchers
Apply or nominate candidates for the “Best paper award 2022” for junior researchers at KI!
This award is made possible thanks to the generosity of Axel och Margaret Ax:son Johnson Foundation for Public Benefit.
The KI Lifestyle4Health “Best paper award 2022” is aimed to reward scientists in early stages of their career for outstanding work.
Closing date: 15 June 2022
Var finns de bästa forsknings- och innovationsprojekten som gör nytta för patienter och sjukvård?
För femtonde året i rad utdelas Athenapriset, Sveriges största pris till forskning och innovationer som kommit till genom samverkan mellan hälso- och sjukvården, akademin och näringslivet.
Ansökningar till priset sker genom en nomineringsprocess. Nomineringen är öppen för alla och det går att föreslå både egna och andras projekt.
Vinnaren av priset får 100 000 kronor i ett forskningsstipendium. Årets prisutdelning sker vid ett webbinarium den 25 oktober kl. 14:30–16:00.
Closing date: 29 May 2022
Nominate Your 2022 RARE Champion
Do you know someone who has made a significant impact this year in rare advocacy, rare industry, rare medical care, science, or is an up-and-coming rare disease leader?
Nominate them for a Champions of Hope award.
All nominees will receive a pin and be celebrated for their contributions on social media. Nominees selected as the RARE Champion in their category will be announced in July and recognized at our Champions of Hope Awards Dinner during the RARE Patient Advocacy Summit in San Diego on Tuesday, September 13, 2022.
Closing date: May 30 2022
Utlysning av medel för alkoholforskning
Systembolagets Alkoholforskningsråd delar årligen ut anslag till olika forskningsprojekt. Samhällsvetenskaplig och folkhälsovetenskaplig alkoholforskning prioriteras, tillsammans med forskning som är av särskild betydelse för det förebyggande arbetet mot alkoholskador. Från och med 2017 delas tio miljoner kronor ut per år, varav två miljoner viks för fokusområden som har identifierats som särskilt angelägna och där mer forskning behövs. Alkoholforskningsrådet ser gärna ansökningar från yngre forskare.
Rådet administreras av Centralförbundet för alkohol- och narkotikaupplysning (CAN).
Closing date: 15 September 2022
European Crohn's and Colitis Organisation (ECCO)
The European Crohn's and Colitis Organisation invites applications for its fellowships. These encourage young individuals in their career and to promote innovative scientific research in inflammatory bowel diseases in Europe.
- Applicants must not be older than 40 years or still in training at the time of application.
- They must have a hosting institute outside their own country which has accepted to host and supervise them and both the applicant and their hosts must be ECCO members.
- Applications are not restricted to individuals from ECCO member countries and applicants may be from non-European countries.
Budget: A total of two awards worth €60,000 each, over one year are available.
The grants support innovative scientific research in the area of inflammatory bowel diseases in Europe.
- Young basic or clinical scientists up to the age of 40, or above if within five years of finishing gastrointestinal training or PhD graduation.
- They must be members of the society.
- Research is usually undertaken at the applicant’s home institution.
Budget: A total of eight awards, worth €80,000 each, are available for one year.
ECCO pioneer award
The European Crohn’s and Colitis Organisation invites proposals for its pioneer award. This aims to encourage and support innovative basic or clinical scientific research in the area of inflammatory bowel diseases across Europe. Projects must be new, original and not yet be launched.
- A multi-centre project group or a single centre may apply.
- All applicants must be members of the organisation.
Budget: One award worth €300,000 for a duration of two years is available.
Deadline: 1 August, 2022
Non-drug approaches grants, Parkinson's UK, GB
Parkinson’s UK invites pre-proposals for its non-drug approaches grants. These support research to develop non-drug approaches for Parkinson's. The focus of the scheme is to improve quality of life for people affected by Parkinson's in the shorter term. Projects may focus on:
- speech and language, physiotherapies and occupational therapies;
- approaches to managing mental health;
- lifestyle changes including exercise and nutrition aids and devices;
- complementary therapies.
- Grants are tenable only at a UK university, NHS Trust, statutory social care organisation or other research institution.
- Principal applicants should hold employment contracts that extend beyond the period of the grant.
- Co-applicants and collaborators may be based at institutions outside the UK or biotech companies.
- Applications related to improving healthcare services will not be considered in this scheme.
Budget: maximum award amount is £200,000 for up to 2 years.
Deadline: 22 June 2022
Early detection and diagnosis project award, Cancer Research UK, GB
Cancer Research UK invites applications for its early detection and diagnosis project award. This supports research projects that drive a transformational change in how and when early cancers and pre-cancerous states are diagnosed. Projects should aim to detect and diagnose consequential precancerous changes and cancer at the earliest possible point at which an intervention might be made, reducing the burden of late-stage disease.
Eligibility: Applicant should
- Have some postdoctoral experience or equivalent
- Be scientists, clinicians or healthcare workers in UK universities, medical schools, hospitals, or research institutes
- Multi-institutional proposals are welcome and awards can be held across institutions in the UK. Supporting roles (co-investigators/collaborators) from international and commercial organisations are welcome.
Budget: Awards are worth up to £500,000 each for up to three years, or four years when funding a PhD.
Deadline: 22 June 2022
Federal Funding agencies
Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional), US
The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, abuse, and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative (find more information in the call text):
- Stage I (treatment generation, refinement)
- Stage II (“Efficacy”)
- Stage III (“Efficacy in Real-World”)
Deadline: August 10, 2022, March 21, 2023, August 10, 2023, March 21, 2024, August 09, 2024, March 21, 2025. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-22-182
Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer, Notice Number: NOT-CA-22-085, US
The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms.
Areas of research interest include, but are not limited to the following:
- Understanding how exogenous cannabis and cannabinoids affect cancer development (preneoplasia through malignancy) and biology, including the tumor microenvironment;
- Understanding how endogenous cannabinoid pathways influence cancer development and biology;
- Defining the effects of cannabis and cannabinoids on cancer treatment (particularly targeted treatments and immunotherapy) and the development of treatment resistance;
- Understanding the use of cannabis and cannabinoids in cancer interception and delineating how endocannabinoid signaling pathways may inhibit early cancers;
- Defining the mechanisms of cannabis and cannabinoid action in alleviating symptoms of cancer and cancer treatment (such as pain, nausea and neuropathy);
- Understanding the combinatorial effects of cannabis and cannabinoids in conjunction with other factors (such as tobacco constituents, alcohol, microbiome or diet) on cancer biology, treatment and symptom management;
- Identifying biological mechanisms underlying disparities in sex or ethnicity in cannabis and cannabinoid action in cancer biology, treatment or symptom management; and
- Developing or validating new and human-relevant model systems to understand cannabis and cannabinoid action in cancer biology, treatment or symptom management.
Deadline: Standard dates apply. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA):
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional, R21), US
The purpose of this FOA is to stimulate research to understand the link between social disconnection – including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) – and suicidal thoughts and behaviors in late-life. For the purposes of this FOA, social disconnection can be characterized by structural components (e.g., objectively few social relationships or infrequent social contact, whether driven by individual choice or societal forces), functional components (e.g., low or insufficient levels of social support and feelings of being excluded), and qualitative components (e.g., perceptions that relationships are of poor quality or are dissatisfying).
Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Putative mechanisms exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental.
Of particular interest is research that identifies neurobiological, behavioral, psychosocial, or environmental mechanisms that can be targets within an experimental therapeutics approach (e.g., the NIH Stage Model) intervention development or that can point to ways to modify existing healthcare and community-based services to better provide support for individuals in late-life in the midst of a suicidal crisis.
Deadline: October 15, 2022. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-MH-22-135 (R01), RFA-MH-22-136 (R21)
More information (R01), (R21)
Research grants, National Multiple Sclerosis Society, US
The National Multiple Sclerosis Society invites applications for its research grants. These support research related to multiple sclerosis (MS) that aim to advance the society’s roadmap of stopping MS disease activity, restoring function and ending MS by preventing new cases. All types of research including laboratory models, human studies, population-based approaches, and data-intensive investigations that leverage both researcher and patient-reported outcomes, are supported. Particularly, studies that focus on the following areas are valued:
- promotion of synergies between researchers in diverse disciplines;
- adherence to principles of sharing data and resources;
- focus on underserved and understudied ethnic and racial MS populations.
Eligibility: Principal investigators may be of any nationality but must hold an MD, PhD or an equivalent qualification.
Budget: Grants are awarded for one to five years and may cover direct costs up to USD 200,000 per year.
Deadline: pre-applications: 5 pm Eastern, July 13, 2022, Full Application Deadline: 5 pm Eastern, July 20, 2022
Path to a cure – collaborative research grant, Cystic Fibrosis Foundation, US
The Cystic Fibrosis Foundation invites applications for its path to a cure – collaborative research grant. This supports collaborative research that will contribute to the development of new therapies of therapeutic strategies to treat cystic fibrosis, with an emphasis on advancing CTFR gene repair and replacement approaches. Projects should utilize technologies and strategies that have the potential to inform or translate into novel therapies to restore CFTR protein function by fixing or replacing the defective CFTR gene. Collaborations that bring new investigators and technologies into the cystic fibrosis research community will be given highest priority.
- Applicants must speak with CFF program staff prior to submission to ensure the research aims are in alignment with the research priorities as described in this RFA. Failure to do so will result in the administrative withdrawal of the proposal.
- International applicants and institutions are required to submit additional information in accordance with USA Patriot Act and the U.S. Department of Treasury Anti-Terrorist Financing Guidelines (more information in the call text).
- Applicants must be independent investigators (an individual who is out of fellowship training and whose institution allows them to submit applications for research funding as a Principle Investigator).
- Applications must focus on one or more of the research areas of interest outlined in Section VI below.
- Applicants who are already funded or seeking funds through other CFF funding mechanisms may apply to this RFA, but the research pograms must be scientifically distinct.
Budget: Up to $1,000,000 direct costs per year for up to three years. The application must consist of at least two projects, each led by an independent investigator. The lead institution may request up to $25,000 direct costs per year to support an administrative core. Plus 12% of indirect costs per year.
Deadline: July 14, 2022 by 5 p.m. ET.